Evidence map›Paper›PMID 20565729›Full record

ArticleJournal of biomedical science2010

Immobilizing topoisomerase I on a surface plasmon resonance biosensor chip to screen for inhibitors.

Hsiang-Ping Tsai, Li-Wei Lin, Zhi-Yang Lai, Jui-Yu Wu, Chiao-En Chen, Jaulang Hwang, Chien-Shu Chen, Chun-Mao Lin

Abstract read
In one paragraph

Article in Journal of biomedical science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Alkaloids isolated from natural herbs as the anticancer agents.Evidence-based complementary and alternative medicine : eCAM · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hsiang-Ping TsaiDepartment of Biochemistry, School of Medicine, Taipei Medical University, Taipei, Taiwan.
Li-Wei Lin
Zhi-Yang Lai
Jui-Yu Wu
Chiao-En Chen
Jaulang Hwang
Chien-Shu Chen
Chun-Mao Lin

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe topoisomerase I (TopI) reaction intermediate consists of an enzyme covalently linked to a nicked DNA molecule, known as a TopI-DNA complex, that can be trapped by inhibitors and results in failure of re-ligation. Attempts at new derivative designs for TopI inhibition are enthusiastically being pursued, and TopI inhibitors were developed for a variety of applications. Surface plasmon resonance (SPR) was recently used in TopI-inhibition studies. However, most such immobilized small molecules or short-sequence nucleotides are used as ligands onto sensor chips, and TopI was used as the analyte that flowed through the sensor chip.

methodsWe established a sensor chip on which the TopI protein is immobilized to evaluate TopI inhibition by SPR. Camptothecin (CPT) targeting the DNA-TopI complex was used as a representative inhibitor to validate this label-free method.

resultsPurified recombinant human TopI was covalently coupled to the sensor chip for the SPR assay. The binding of anti-human (h)TopI antibodies and plasmid pUC19, respectively, to the immobilized hTopI was observed with dose-dependent increases in resonance units (RU) suggesting that the immobilized hTopI retains its DNA-binding activity. Neither CPT nor evodiamine alone in the analyte flowing through the sensor chip showed a significant increase in RU. The combination of pUC19 and TopI inhibitors as the analyte flowing through the sensor chip caused increases in RU. This confirms its reliability for binding kinetic studies of DNA-TopI binders for interaction and for primary screening of TopI inhibitors.

conclusionsTopI immobilized on the chip retained its bioactivities of DNA binding and catalysis of intermediates of the DNA-TopI complex. This provides DNA-TopI binders for interaction and primary screening with a label-free method. In addition, this biochip can also ensure the reliability of binding kinetic studies of TopI.

Indexed as

Enzymes, ImmobilizedTopoisomerase I InhibitorsCamptothecinComet AssayDNADNA DamageDNA Topoisomerases, Type IDrug Evaluation, PreclinicalEnzyme InhibitorsHumansIn Vitro TechniquesKineticsMacromolecular SubstancesModels, MolecularPlant ExtractsQuinazolinesCamptothecinDNADNA Topoisomerases, Type IEnzyme InhibitorsEnzymes, ImmobilizedevodiamineMacromolecular SubstancesPlant ExtractsQuinazolinesRecombinant ProteinsTopoisomerase I Inhibitors

Identifiers

PMID20565729
PMCPMC2898767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.